MORAIYA PLANT
Infy, Bajaj Finserv among stocks seeing surge in trader interestET takes a look at stocks seeing interest in the November futures and options series.
- Worst is over for the pharma sector. What investors should do
Though short-term pressure will continue, risk-reward is getting in favour of this sector.
- Analyst Calls: Bharti Infratel, UltraTech Cement, Ashok Leyland, HDFC, Cadila Healthcare
CLSA has retained sell rating on Bharti Infratel with a target price of Rs 250.
- Buy Cadila Healthcare, target Rs 315: Nirmal Bang Securities
Cadila Healthcare is a largecap company, operating in pharmaceuticals and health care sector.
- CLSA downgrades Cadila Healthcare to 'sell'
US FDA recently inspected Cadila's Moraiya facility and issued a Form 483 with 14 observations.
- CLSA upgrades Cadila Healthcare to 'buy'
Shares of Cadila ended down 1.74 per cent at Rs 369.95 on the BSE on Friday.
- Zydus Cadila shares rise 3.41% after USFDA clears Moraiya plant
The USFDA inspected Cadila’s Moraiya facility from August 31-September 7.
- Cadila receives audit closure report
The Moraiya manufacturing plant had completed the USFDA audit from February 6th to 15th 2017 with Zero 483 observations, the company said.
- Will bring our latest drug Lialda by August: Nitin Kumar Parekh, Director - Finance, Cadila
Cadila will bring out its latest drug, Lialda, in July or August, revealed Nitin Kumar Parekh, Director - Finance, Cadila.
- Cadila Healthcare surges 7% on receiving USFDA approval for levofloxacin injection
The stock climbed 7.18 per cent to hit a high of Rs 504.8 on BSE.
- Zydus Cadila gets USFDA nod for levofloxacin injection
The Gujarat group has more than 115 approvals and has so far filed over 300 abbreviated new drug applications (ANDAs) since it commenced fi...
- CLSA raises target price of Cadila Healthcare; should you buy?
The global brokerage house said, “Moraiya outcome a big surprise but approvals may take time.” CLSA believes benefits of Moraiya's clearanc...
- USFDA inspects Cadila Healthcare's Moraiya facility
"USFDA inspected company's Moraiya facility from February 6, 2017 to February 15, 2017. At the end of the inspection no observation (483) i...
- USFDA to re-inspect Cadila Healthcare's unit
- USFDA to re-inspect Cadila Healthcare's unit
- Cadila Healthcare gets EIR for Ahmedabad plant from USFDA
"The company's Oral Solid Dosage drug manufacturing plant located at SEZ, Ahmedabad has received an Establishment Inspection Report (EIR) f...
- Cadila gets EIR from USFDA for Changodar facility
Last month, Cadila Healthcare had received Establishment Inspection Report (EIR) from the US health regulator for its manufacturing facilit...
- US FDA points to loose quality controls, data deletions at Zydus Cadila’s two facilities
The letter of December 23 stated examples of data deletions at the Moraiya and the unit’s failure to “adequately control the use of compute...
- Cadila gets US FDA warning for violating standards at Moraiya and Ahmedabad plants
The company said its Moraiya and Ahmedabad facilities have been cited in the letter, and it is working on responding to the FDA concerns re...
MORE NEWS
